NCT06486792View on ClinicalTrials.gov

Stroke Prevention In Ischemic Stroke With Covert Atrial Fibrillation

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

1,148

Participants

Timeline

Start Date

September 1, 2024

Primary Completion Date

September 1, 2025

Study Completion Date

March 1, 2028

Conditions
StrokeIschemic StrokeCerebral InfarctionAtrial Fibrillation
Interventions
DRUG

Apixaban

Patients who have had an ischemic stroke will receive either an anticoagulant or aspirin according to their randomization arm.

DRUG

Aspirin

Aspirin is used as the standard of care

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT06486792 - Stroke Prevention In Ischemic Stroke With Covert Atrial Fibrillation | Biotech Hunter | Biotech Hunter